What is Bicycle Therapeutics Ltd's share price today?
Bicycle Therapeutics Ltd (BCYC) share price today is $3.54 as of October 24, 2026 at 1:29 AM IST. The stock touched a day high of $3.59 and a day low of $3.41.What exchange does Bicycle Therapeutics Ltd stock trade on, and under what ticker symbol?
Bicycle Therapeutics Ltd stock trades on NASDAQ under the ticker symbol BCYC.What is Bicycle Therapeutics Ltd's market capitalization?
Bicycle Therapeutics Ltd's market capitalization is $249.87M as of October 24, 2026 at 1:29 AM IST.What is Bicycle Therapeutics Ltd's price-to-earnings (P/E) ratio?
Bicycle Therapeutics Ltd's price-to-earnings (P/E) ratio is N/A as of October 24, 2026.What is Bicycle Therapeutics Ltd's price-to-book (P/B) ratio?
Bicycle Therapeutics Ltd's price-to-book (P/B) ratio is 0.49 as of October 24, 2026.Can Indian investors buy Bicycle Therapeutics Ltd shares?
Yes, You can buy Bicycle Therapeutics Ltd shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Bicycle Therapeutics Ltd shares from India?
Indian investors can buy Bicycle Therapeutics Ltd shares in three steps: 1. Search Bicycle Therapeutics Ltd on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Bicycle Therapeutics Ltd shares for Indian investors?
Since Bicycle Therapeutics Ltd trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Bicycle Therapeutics Ltd shares via Tickertape?
Indian investors can start investing in Bicycle Therapeutics Ltd (BCYC) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 2.8192 shares at the current price of $3.54.
$
₹
$3.542.55% (-0.09)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
0.49
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-2.73
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
0%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 9 analysts reports
Buy6 analysts
Hold3 analysts
Sell0 analyst
Price Upside
+167.61%
Earnings Growth
+22.35%
Rev. Growth
-75.84%
Company Profile
Company Profile
ABBV
P/E Ratio
80.45
80.45
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
AMGN
P/E Ratio
27.22
27.22
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
P/E Ratio
30.37
30.37
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
MRNA
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$3.55Baseline
Analyst Target - 1 year
Target$9.5+167.61%
All values in $
2026
Current$3.55Baseline
Analyst Target - 1 year
Target$9.5+167.61%
All values in $
Revenue Forecast
Revenue Forecast
Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.
The next fiscal year's mean estimate implies -75.84% growth, versus a trailing 3-year CAGR of 71.21%.
2025
Current$72.58Baseline
Forecast for Dec 2026
High$37.58-48.22%
Average$17.53-75.84%
Low$2.66-96.33%
All values in $ Million
2025
Current$72.58Baseline
Forecast for Dec 2026
High$37.58-48.22%
Average$17.53-75.84%
Low$2.66-96.33%
All values in $ Million
Earnings Per Share Forecast
Earnings Per Share Forecast
2025
Current$-3.16Baseline
Forecast for Dec 2026
High$-1.34+57.59%
Average$-2.45+22.35%
Low$-2.8+11.39%
All values in $
2025
Current$-3.16Baseline
Forecast for Dec 2026
High$-1.34+57.59%
Average$-2.45+22.35%
Low$-2.8+11.39%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 19.53 | 9.36 | 2.67 | 3.70 | 9.97 | 2.92 | 11.73 | 47.95 | 0.88 | 0.62 |
Gross Profit | 19.53 | 9.36 | -42.97 | -52.36 | -47.29 | -68.10 | 11.73 | 47.95 | 0.88 | 0.62 |
| Net Income | -26.56 | -39.81 | -50.80 | -51.85 | -60.75 | -78.95 | -59.1 | -20.15 | -60.82 | -50.33 |
| Net Profit Margin | -136.01% | -425.29% | -1898.43% | -1398.43% | -608.94% | -2703.83% | -503.66% | -42.02% | -6857.38% | -8002.06% |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
Compare valuation on Screener| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Bicycle Therapeutics Ltd | - | 0.49 | - |
| AbbVie Inc | 80.45 | 50.45 | 0.54 |
| Amgen Inc | 27.22 | 18.78 | 2.45 |
Price Comparison
Price Comparison
Compare BCYC with any stock or ETFCompare BCYC with any stock or ETF
Comparing from
BCYC
ABBV
AMGN
The 12-month consensus target implies 167.61% growth, versus a trailing 3-year CAGR of -39.12%.